CMS — the Centers for Medicare & Medicaid Services — sets the federal coverage rules that drive GLP-1 reimbursement for the largest single payer base. Coverage on this site has tracked the IRA-driven Medicare Part D price negotiations, the obesity-vs-cardiovascular indication framing, and the state Medicaid follow-on decisions.
The SELECT trial pushed the conversation forward by giving Wegovy a cardiovascular outcomes label that opens reimbursement under existing CV coverage rules — a workaround for the legacy Medicare exclusion of weight-loss drugs. CMS guidance updates in 2025 and 2026 have parsed exactly which Medicare beneficiaries qualify.
Stories here cover CMS rulings, Part D negotiations, and the state Medicaid follow-on. See #medicare for the broader thread and #pricing for the cost context.
After CVS/Aetna, UnitedHealth, and other insurers declined to participate in the BALANCE five-year pilot, CMS announced the Medicare GLP-1 Bridge program — originally scheduled to end December 31, 2026 — will now be extended through 2027 with the federal government directly paying for seniors' obesity drug coverage. The pivot acknowledges that the insurer-funded pilot structure was untenable; CMS said the extension will allow longer data collection on which patients benefit most before any transition back to private payers.
The Trump administration on April 22 cancelled the five-year BALANCE Medicare model that would have had private insurers pay for Wegovy and Zepbound as a regular benefit, after CVS opted out citing a projected $1.4 billion cost over 10 years. Medicare will instead cover the drugs directly through the Medicare GLP-1 Bridge from July 1, 2026 through December 31, 2027, with beneficiaries paying $50/month copays.
April 20, 2026 is the CMS application deadline for Medicare Part D plans to participate in the BALANCE Model, which will offer Wegovy, Zepbound KwikPen, and Foundayo at $50 copay with a $245/month net price starting July 1. CMS added Foundayo to the Medicare GLP-1 Bridge on April 6 following FDA approval, extending coverage to Lilly's new oral GLP-1.